Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
Express News | Windtree Announces Istaroxime Presentation by Cardiogenic Shock Thought Leader at Cardiovascular Clinical Trials Conference
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
H.C. Wainwright Maintains Windtree Therapeutics(WINT.US) With Hold Rating
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Mixed Wednesday Afternoon
Windtree Therapeutics Engages Strategic Adviser to Evaluate Options for Cardiovascular Portfolio; Shares Fall
Windtree Announces Partnership With New Growth Advisors To Leverage Phase 2 Istaroxime Study In Cardiogenic Shock For A Potential Strategic Transaction
Express News | Windtree Therapeutics Inc - May Receive up to $138 Million in Milestones From Lee's Pharmaceuticals
Express News | Windtree Therapeutics Inc - Lee's Pharmaceuticals to Start Phase 3 in Acute Heart Failure in H1 2025
Express News | Windtree: If a Deal Is Consummated for Cardiovascular Portfolio, Plans to Use Some Proceeds to Support Advancement of Oncology Platform
Express News | Windtree Therapeutics Inc: Engaged New Growth Advisors as Its Strategic Advisor to Lead a Process in Respect of Windtree's Cardiovascular Portfolio
Express News | Windtree Announces Partnership With New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
HC Wainwright & Co. Reiterates Neutral on Windtree Therapeutics, Maintains $7 Price Target
Windtree Therapeutics Analyst Ratings
8-K: Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
Express News | Windtree Therapeutics: Believe We Have Sufficient Resources Available to Fund Business Operations Through Jan 2025
Express News | Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
Press Release: Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
No Data